Pharma Companies Make Recommendations to Enhance Credibility of Clinical Trial Publications

A group of pharmaceutical companies has issued a list of recommendations for improving the transparency and credibility of industry-supported clinical research. The recommendations include:

  • Making all findings (including negative findings) public
  • Disclosing potential conflicts of interest by publication authors
  • Disclosing sources of contributions to journal articles
  • Standardizing the reporting of adverse events, and describing adverse events in a way that is clinically meaningful
  • Providing complete information on the research protocol and the methods used to analyze the resultant data
  • Allowing publication authors to access all data from the trial

Editors of several prominent journals also participated in the working group, which published its findings in the Mayo Clinic Proceedings.

Share This Post